The high prevalence of ER/PR co-expression and validated survival difference provides a rationale for further testing the efficacy of hormonal therapy in women diagnosed with hormone receptor positive ovarian endometrioid carcinoma, perhaps in scenarios such as maintenance therapy in stage IC/II disease or at recurrence. This evidence concerns the gene PGR and ovarian endometrioid carcinoma.